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Abstract
Aims
Carotid intima media thickness (CIMT) predicts cardiovascular (CVD) events, but the pre-
dictive value of CIMT change is debated. We assessed the relation between CIMT change
and events in individuals at high cardiovascular risk.
Methods and results
From 31 cohorts with two CIMT scans (total n = 89070) on average 3.6 years apart and clini-
cal follow-up, subcohorts were drawn: (A) individuals with at least 3 cardiovascular risk
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factors without previous CVD events, (B) individuals with carotid plaques without previous
CVD events, and (C) individuals with previous CVD events. Cox regression models were fit
to estimate the hazard ratio (HR) of the combined endpoint (myocardial infarction, stroke or
vascular death) per standard deviation (SD) of CIMT change, adjusted for CVD risk factors.
These HRs were pooled across studies.
In groups A, B and C we observed 3483, 2845 and 1165 endpoint events, respectively.
Average common CIMT was 0.79mm (SD 0.16mm), and annual common CIMT change
was 0.01mm (SD 0.07mm), both in group A. The pooled HR per SD of annual common
CIMT change (0.02 to 0.43mm) was 0.99 (95% confidence interval: 0.95–1.02) in group A,
0.98 (0.93–1.04) in group B, and 0.95 (0.89–1.04) in group C. The HR per SD of common
CIMT (average of the first and the second CIMT scan, 0.09 to 0.75mm) was 1.15 (1.07–
1.23) in group A, 1.13 (1.05–1.22) in group B, and 1.12 (1.05–1.20) in group C.
Conclusions
We confirm that common CIMT is associated with future CVD events in individuals at high
risk. CIMT change does not relate to future event risk in high-risk individuals.
Introduction
Carotid intima media thickness (CIMT) has been debated as a screening tool[1,2] and as a sur-
rogate marker of vascular event risk.[3] Recent publications have raised doubts about the clini-
cal usefulness,[4] and of the surrogacy[5,6] of CIMT. In a large study on general population
individuals without prevalent cardiovascular disease (CVD), we were unable to show an asso-
ciation between rate of change of CIMT estimated by two measurements assessed some years
apart and the subsequent risk of future CVD events, although the association between CIMT,
estimated as an average of the two CIMT measures at different time points, and future risk was
robust and consistent.[7]
Several hypotheses have been suggested to explain this discrepancy. One credible argument
is that the small CIMT change, assessed with reasonable to considerable measurement error in
cohort studies, and the low event risk in the asymptomatic general population make it difficult
to discern such association. Acting on this hypothesis, we aimed to study individuals at high
risk, to explore whether a relation between CIMT change and CVD event risk is present. For
the present analyses, we identified studies that included asymptomatic individuals with at least
three CVD risk factors, asymptomatic individuals with carotid plaque, and individuals with
pre-existing CVD as indicators of high risk. With individual participant data (IPD) meta-anal-
ysis we assessed the relation between CIMT, CIMT change, and subsequent vascular event risk
in these groups.
Materials and methods
To identify relevant studies for this meta-analysis, we performed a comprehensive literature
research. With the search terms “intima media” AND (“myocardial infarction” OR”stroke”
OR”death” OR “mortality”) we screened PubMed. In addition, we hand searched reference
lists of CIMT review papers. We included publications in all languages, published until 1st
October 2015. Using predefined inclusion criteria (Table 1), original articles and research
reports were assessed by reading both the abstracts and the full texts. When eligibility for our
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analysis could not be decided, we sent a short screening questionnaire to the relevant study
team. If a study fulfilled all inclusion criteria, the study team was invited to join the collabora-
tion, share their data, and participate in the project. We included cohorts with at least two
CIMT scans several years apart, and a subsequent clinical follow-up.
The datasets underwent central plausibility checks and transformation into a standard data
format with uniform variable names, units, and coding. Ordinal variables were recoded into
binary balanced categories. Mean common carotid IMT (mean CCA-IMT) was calculated as
the mean from all available mean CIMT measurements in the common carotid arteries,
including left and right carotids, near and far wall, and all insonation angles. From the first
two ultrasound visits of each study, two CIMT variables were derived: ‘average CIMT’ is the
mean of the baseline and the first follow-up scan; and ‘annual CIMT change’ is the difference
between the baseline and the first follow-up scan, divided by the time between scans in years.
Mean CCA-IMT was used in most analyses, in some sensitivity analyses we used maximal
CCA-IMT in the same way. Differences in the ultrasound measurement protocols between
studies were tabulated and considered in sensitivity analyses.
We used a combined endpoint for most analyses, defined as the first event of myocardial
infarction (MI), stroke (including non-traumatic intracerebral hemorrhage), or vascular
death, occurring after the second ultrasound visit. For these component endpoints, the defini-
tion used in each study was adopted. When vascular death was not available in a study, total
mortality was used instead. For some sensitivity analyses, we also studied the endpoints MI,
stroke, and total mortality separately.
From all cohorts except one, IPD were sent to the coordinating center at Frankfurt Univer-
sity, where they were harmonized. The harmonized data were forwarded to the statistics center
at Cambridge University for fitting of the Cox models and pooling of their estimates. One
cohort (AtheroGene) was unable to forward IPD due to legal restrictions. For this cohort, the
plausibility checks and the fitting of the Cox models were done locally, following the program-
ming codes developed by the statistics center, and their estimates were sent to Cambridge for
pooling.
Statistical analyses
In order to identify individuals with high CVD risk, we used three subject groups:
A) Individuals with three or more CVD risk factors, including (i) male sex or age 60
years, (ii) LDL cholesterol>160mg/dl and/or lipid-lowering medication, (iii) HDL
cholesterol<40mg/dl, (iv) systolic blood pressure>140mmHg, diastolic blood
Table 1. Inclusion criteria.
Population cohorts Risk cohorts
Prospective longitudinal study design
Investigation of a population based sample or a sample similar
to the general population
Investigation of one, or including one of the
following risk populations:
• Individuals with at least 3 CVD risk factors
• Individuals with carotid plaque
• Individuals with previous MI or stroke
Well-defined and disclosed inclusion criteria and recruitment strategy
At least two ultrasound visits where carotid IMT was determined
A clinical follow-up after the second ultrasound visit, recording MI, stroke, death, vascular death or a subset of
these.
A minimum of 10 events per endpoint before exclusions
https://doi.org/10.1371/journal.pone.0191172.t001
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pressure>90mmHg and/or antihypertensive medication, (v) prediagnosed diabetes or
fasting glucose>110mg/dl and/or antidiabetic medication, (vi) current smoking, (vii) tri-
glycerides >200mg/dl and (viii) family history of CVD, without previous MI or stroke.
This definition followed the inclusion criteria of the IMPROVE study[8];
B) Individuals with carotid plaques without previous MI or stroke, irrespective of the num-
ber of risk factors;
C) Individuals with previous MI or stroke.
From general population cohorts, individuals satisfying these respective criteria were
selected. Cohorts in dedicated risk groups and hospital cohorts were included when they
matched our criteria, or a relevant proportion of their individuals could be selected by our
criteria.
The statistical analysis followed a pre-specified plan. For cohorts A and B, individuals who
had a CVD event (MI or stroke) before the second ultrasound visit were excluded. In cohort
C, individuals with endpoint events between the two ultrasound visits were excluded. For
every study, considering clinical events after the second ultrasound visit, we fitted a Cox
regression model for the chosen endpoint (usually combined: MI or stroke or vascular death).
The hazard ratio (HR) of annual CIMT change was expressed per (within study) standard
deviation (SD) of annual CIMT change. Two levels of adjustment were defined: model 1
included age, sex, and average CIMT, and model 2 included these covariates plus a large set of
CVD risk factors (ethnicity, socioeconomic status, body mass index, systolic blood pressure,
antihypertensive medication, total cholesterol, lipid-lowering medication, diabetes, smoking
status, hemoglobin, creatinine). The log HR estimates were then pooled across all studies using
random effects meta-analysis.[9] Heterogeneity between the cohorts was assessed using the I2
statistic.[10] If multiple studies had each less than 20 endpoint events, a Cox regression model
was fitted on a merged dataset of these, stratified for the cohort, and the resulting HR was
pooled with the HRs of the other cohorts. The effects of study-level variables were assessed by
random effects meta-regression. All analyses were based on unimputed data (complete case
analysis) since previous work had shown no material differences when using multiple imputa-
tion.[7]
The rationale and methods of the PROG-IMT project have been published beforehand.[11]
The first author had full access to the data (except the IPD of AtheroGene, as explained above)
and takes responsibility for their integrity. All authors have read and agreed to the manuscript
as written. The PROG-IMT project and the work leading to this publication have been
approved by the Ethics Committee of Frankfurt University Hospital (Geschaeftsnummer 304/
13). All contributing studies had approval of their local IRB.
Results
2513 publications were screened and 610 screening questionnaires sent. After the screening
process, 60 cohorts were known to be eligible (S1 Fig). Of these, 18 declined collaboration, and
9 accepted but did not provide their dataset in time. We were able to include 23 population
cohorts and 10 risk cohorts across the world. One population cohort and one risk cohort had
to be excluded subsequently, because after the construction of the groups A-C, no endpoint
events were left. The remaining cohorts are shown in Table 2. In group A, 23406 individuals
were included, of which 3462 suffered an endpoint event. In group B, 14496 individuals with
2852 endpoint events were analyzed. Group C comprised 3628 individuals who developed
1174 endpoint events. Given our criteria, the subjects selected into group C did not overlap
with those in group A or B, but A overlapped with B in 17 cohorts (by 24–79% of group A). In
Common CIMT, CIMT change and vascular events in high risk individuals
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the Cardiovascular Health Study (CHS), individuals of Caucasian ethnicity (cohort 1) had a
different follow-up regime than African Americans (cohort 2): they were considered as two
separate cohorts (CHS1 and CHS2).
Table 2. Cohorts and subsamples.
Cohort Cohort
type
Country Mean
age
(years)
Mean duration
between the
first 2
ultrasound
visits (years)
Mean clinical
follow-up after
the second
ultrasound visit
(years)
Total
number of
individuals
(combined
endpoint
events)
Number of
individuals
(combined
endpoint events)
included in A (at
least 3 RF)
Number of
individuals
(combined
endpoint events)
included in B
(carotid plaque)
Number of
individuals
(combined
endpoint events)
included in C
(previous CVD
event)
AIR[12] Population Sweden 58.2 3.2 5.5 391 (23) 129 (9) 106 (6) n.a.
ARIC[13] Population USA 54.2 2.9 14.2 15040 (2089) 4486 (933) 3672 (707) 408 (176)
AtheroGene
[14]
Hospital Germany 62.4 0.6 5.9 335 (36) 181 (14) n.a. 154 (22)
BHS[15] Population USA 36.3 2.5 4.5 1392 (13)# 179 (2) n.a. n.a.
Bruneck[16] Population Italy 62.9 5.0 8.3 821 (113) 372 (58) n.a. 61 (23)
CAPS[17] Population Germany 51.0 3.2 5.2 6972 (151)+ 610 (40) n.a. 95 (27)
CCCC[18] Population Taiwan 54.9 5.0 6.9 3602 (116)+ 456 (47) 250 (32) 25 (2)
CHS1[19] Population USA 72.8 2.9 8.5 5201 (1943) 1957 (750) 2633 (963) 777 (358)
CHS2[19] Population USA 73.0 6.0 5.0 687 (206) 177 (42) 217 (50) 58 (16)
CMCS[20] Population China 59.9 5.4 4.9 1324 (28) 369 (8) 182 (3) 43 (2)
CSN[21] Risk
population
Italy 55.0 2.5 3.6 13843 (14) 1374 (1) n.a. n.a.
DIWA[22] Population Sweden 64.5 5.4 2.4 644 (53) 259(9) n.a. 26 (4)
EAS[23] Population UK 69.0 6.6 5.3 1593 (316) 513 (29) 381 (22) 93 (11)
EPICARDIAN
[24]
Population Spain 67.7 3.1 5.6 446 (53) 156 (19) n.a. 9 (1)
EVA[25] Population France 65.1 2.0 14.0 1135 (41)# 594 (25) 182 (13) 81 (6)
HOORN[26] Population Netherlands 68.2 5.2 2.7 3103 (458) 123 (1) n.a. 7 (0)
IMPROVE[27] Risk
population
Finland,
France, Italy,
Netherlands,
Sweden
64.2 1.2 1.8 3703(49) 2471 (41) n.a. n.a.
INVADE[28] Population Germany 67.7 2.2 3.9 3908 (602)+ 1183 (135) 1319 (138) 408 (97)
KIHD[29] Population Finland 52.4 4.1 13.7 1399 (478) 669 (216) 239 (96) 98 (54)
Landecho
et al.[30]
Hospital Spain 54.5 3.6 3.2 250 (11) 124 (5) n.a. n.a.
MDCS plaque
substudy[31]
Risk
population
Sweden 59.5 2.1 12.2 1544 (260) 654 (157) n.a. 31 (12)
Niguarda-
Monzino[32]
Hospital Italy 56.2 3.4 4.1 1790 (101) 168 (7) n.a. n.a.
NOMAS/
INVEST[33]
Population USA 65.5 3.6 2.9 778 (27) 378 (15) 344 (18) n.a.
OSACA-2[34] Hospital Japan 65.0 2.8 6.0 291 (13) 79 (2) n.a. 109 (8)
PIVUS[35] Population Sweden 70.0 5.1 1.9 1017 (114)++ 386 (17) 398 (15) 65 (2)
PLIC[36] Population Italy 55.2 2.2 4.1 1782 (25) 759 (11) 343 (10) 88 (4)
RIAS[37] Hospital Switzerland 64.4 2.7 4.8 145 (43) 11 (4) n.a. 54 (14)
Rotterdam[38] Population Netherlands 70.6 6.5 5.5 7983 (4011)+ 1192 (317) 1227 (310) 383 (160)
SAPHIR[39] Population Austria 51.4 4.6 8.5 1800 (70) 445 (32) 286 (17) 39 (3)
SHIP[40] Population Germany 49.8 5.3 5.9 4308 (127) 1262 (71) 1006 (63) 130 (18)
SPARC[41] Hospital Canada 70.3 1.1 2.1 349 (23) 182 (5) n.a. n.a.
(Continued)
Common CIMT, CIMT change and vascular events in high risk individuals
PLOS ONE | https://doi.org/10.1371/journal.pone.0191172 April 12, 2018 6 / 19
The distributions of average common CIMT, annual CIMT change, and of crude event
rates are summarized by cohort and subgroup in S1 Table. The mean time interval between
the first and second ultrasound visit was 3.57 years. Mean average common CIMT ranged
from 0.68 to 1.10mm (mean 0.79mm, SD 0.16mm), and mean annual CIMT change from
-0.10 to 0.05 mm/year (mean 0.01mm, SD 0.07mm, both group A). The study-specific SD for
average common CIMT ranged from 0.09 to 0.75mm, the study-specific SD of annual CIMT
change varied between 0.02 and 0.43mm. After the second ultrasound measurement, partici-
pants were followed up for endpoind events on average for 7.1 years. The crude event rates var-
ied between 0.2 and 82.9 events per 1000 person years (average 19 events per 1000 person
years).
In Fig 1 we show the association between annual common CIMT change and the combined
endpoint in all three groups. There was no significant relation in any group, whether adjusted
for CVD risk factors or not. Between the cohorts, I2 statistics indicated no substantial hetero-
geneity. Fig 2 displays the relation between average common CIMT and the combined end-
point. In all three groups, there were significant and consistent positive associations, which
attenuated on adjustment for CVD risk factors; the HRs were somewhat heterogeneous
between the cohorts (statistically significant in groups A and B). Sensitivity analyses showed
very similar results for the separate endpoints MI, stroke, and total mortality; and also for max-
imal CCA-IMT (shown for group A in S2–S5 Figs). To allow for a non-linear association, we
assessed the association between CIMT and risk in Cox regression model including a quadratic
term of CIMT change. We found a HR of 0.98 (95% CI 0.95–1.02) per SD of annual mean
CCA-IMT progression (I2 = 10.9%, p for heterogeneity = 0.331) and of 1.22 (1.14–1.30) per
SD of average mean CCA-IMT (i2 = 60.6%, p for heterogeneity = 0.001) for the combined
endpoint.
In three cohorts (ARIC, INVADE, KIHD), CIMT measurements were available from four
visits. In these cohorts, we estimated the correlation between the annual common CIMT
Table 2. (Continued)
Cohort Cohort
type
Country Mean
age
(years)
Mean duration
between the
first 2
ultrasound
visits (years)
Mean clinical
follow-up after
the second
ultrasound visit
(years)
Total
number of
individuals
(combined
endpoint
events)
Number of
individuals
(combined
endpoint events)
included in A (at
least 3 RF)
Number of
individuals
(combined
endpoint events)
included in B
(carotid plaque)
Number of
individuals
(combined
endpoint events)
included in C
(previous CVD
event)
Tromsø[42] Population Norway 59.5 6.3 8.0 4827 (850) 2091 (461) 1711 (389) 540 (176)
included in sensitivity analyses only
+combined endpoint MI or stroke or death
#vascular death
++total mortality
AIR = Atherosclerosis and Insulin Resistance Study; ARIC = Atherosclerosis Risk in Communities; BHS = Bogalusa Heart Study; CAPS = Carotid Atherosclerosis
Progression Study; CCCC = Chin-Shan Community Cardiovascular Cohort Study; CHS = Cardiovascular Health Study; CMCS = Chines multi-Provincial Cohort
Study; CSN = The Campania Salute Network; DIWA = Diabetes and Impaired Glucose Tolerance in Women and Atherosclerosis; EAS = Edinburgh Artery Study; EVA
= E´tude de Vieillissement Arterie´l; IMPROVE = Carotid Intima-Media Thickness and IMT-Progression as Predictors of Vascular Events in a High Risk European
Population; INVADE = Interventionsprojekt zerebrovaskula¨re Erkrankungen und Demenz im Landkreis Ebersberg; KIHD = Kuopio Ischemic Heart Disease Risk
Factor Study; MDCS = Malmø Diet and Cancer Study; NOMAS = Northern Manhattan Study; INVEST = Oral Infections and Vascular Disease Epidemiology Study;
OSACA = Osaca Follow-up Study for Atherosclerosis; PIVUS = Prospective Investigation of the Vasculature in Uppsala Seniors; PLIC = Progression of Lesions in the
Intima of the Carotid; RIAS = Resistive Index in Atherosclerosis; SAPHIR = Salzburg Atherosclerosis Prevention program in subjects at High Individual Risk;
SHIP = Study of Health in Pomerania; SPARC = Progression of Carotid Plaque volume predicts cardiovascular events
https://doi.org/10.1371/journal.pone.0191172.t002
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change from visit 1 to visit 2, with the annual CIMT change from visit 3 to visit 4. This correla-
tion was -0.021 in ARIC (p = 0.60), -0.065 in INVADE (p = 0.11), and -0.082 in KIHD
(p = 0.11).
We studied the influence of the accuracy of CIMT measurement on the association between
annual common CIMT change and risk in meta-regression analyses. There was no significant
relation between the year of the study start and the HR for the combined endpoint per SD of
annual common CIMT change (S6 Fig). Fig 3 shows the meta-regression of the correlation
between the two CIMT measurements (as an indicator of measurement precision) and the
HR, again with no significant relation. To assess the influence of the ultrasound protocol, we
repeated the meta-analysis for individuals with prevalent carotid plaques (group B) and
grouped the cohorts into those where CIMT measurement included carotid plaques and those
where plaques were avoided (S7 Fig). The pooled HR for the combined endpoint did not differ
between these two groups.
Discussion
Within a global collaborative project (see www.prog-imt.org), we managed to amass a large
proportion of the worldwide available data in high-risk individuals (52% of all eligible
cohorts), in order to assess the association between common CIMT change, and vascular
event risk. Even in the selected high-risk individuals studied here, we were unable to demon-
strate any association. In contrast, the known association between CIMT and vascular event
risk was reproduced in a very consistent way.
There may be both methodological reasons and biological explanations for this discrepancy.
One key methodological finding is that, even in high-risk populations, annual CIMT change
was not a stable property of individuals, and therefore not a reproducible biomarker. When we
compared–in three cohorts with the necessary data–CIMT change from visit 1 to visit 2 with
CIMT change from visit 3 to visit 4 (all several years apart), we found no correlation.
But what is behind this lack of reproducibility? As can be seen in S1 Table, the range of
common CIMT change, compared to CIMT, is very wide both within and between cohorts,
indicating that measurement error is a major issue. For example in group A, average common
CIMT is 3 to 8fold higher than its study-specific standard deviation, whereas annual common
CIMT change is always smaller than its SD. It is plausible that the small systematic changes of
CIMT within a few years are dwarfed by measurement error and random fluctuations.
A key problem of measuring CIMT change is to pinpoint the exact same measurement site
in the carotid artery, years after the first measurement, and often done by a different techni-
cian. Despite multiple provisions in the ultrasound protocols, this seems to be an unresolved
problem. As many of the studies shown here–and in particular the largest of them–were
planned and started decades ago, we may hope that the newest studies and trials perform bet-
ter. At least among the available cohorts, neither the year of study start, nor the accuracy of
CIMT measurement had any significant effect on the CIMT-risk association we studied.
A plausible biological reason for these null findings is the complexity of the atherosclerotic
process. CIMT reflects not only atherosclerosis, but also an adaptive component of the
Fig 1. Forest plots of the HR of the combined endpoint per one SD of annual mean CCA-IMT change (with 95% CIs). Panel I: Group A (asymptomatic individuals
with three or more CVD risk factors), HR adjusted for age, sex and average mean CCA-IMT (model 1). Panel II: Group A (asymptomatic individuals with three or more
CVD risk factors), HR adjusted for age, sex, average mean CCA-IMT and other CVD risk factors (model 2). Panel III: Group B (asymptomatic individuals with carotid
plaques), HR adjusted for age, sex and average mean CCA-IMT (model 1). Panel IV: Group B (asymptomatic individuals with carotid plaques), HR adjusted for age, sex,
average mean CCA-IMT and other CVD risk factors (model 2). Panel V: Group C (individuals with previous CVD events), HR adjusted for age, sex and average mean
CCA-IMT (model 1). Panel VI: Group C (individuals with previous CVD events), HR adjusted for age, sex, average mean CCA-IMT and other CVD risk factors (model
2).
https://doi.org/10.1371/journal.pone.0191172.g001
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Fig 2. Forest plots of the HR of the combined endpoint per one SD of average mean CCA-IMT (with 95% CIs). Panel I: Group A (asymptomatic individuals with
three or more CVD risk factors), HR adjusted for age, sex and annual mean CCA-IMT change (model 1). Panel II: Group A (asymptomatic individuals with three or
more CVD risk factors), HR adjusted for age, sex, annual mean CCA-IMT change and other CVD risk factors (model 2). Panel III: Group B (asymptomatic individuals
Common CIMT, CIMT change and vascular events in high risk individuals
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muscular wall, sometimes referred to as ‘remodelling’ [43–48]. In addition, in patients with
high event risk, focal plaques may superimpose CIMT. Although overall, CIMT and plaques
are progressing in parallel, there are individuals with low CIMT and impressive plaques (focal
type), and vice versa (diffuse type of atherosclerosis).[49] Risk factors can act differently on
CIMT and plaques,[50–52] and the association between plaque and CVD event risk may be
closer than between CIMT and risk.[53]
In sensitivity analyses we studied cohorts where plaques were excluded from the CIMT
measurement separately, but found no significant differences. However, it may not always be
possible to avoid focal lesions when they are very distinct, and in the ultrasound measurement,
the differentiation between diffuse (CIMT) and focal (plaque) atherosclerotic lesions is not
with carotid plaques), HR adjusted for age, sex and annual mean CCA-IMT change (model 1). Panel IV: Group B (asymptomatic individuals with carotid plaques), HR
adjusted for age, sex, annual mean CCA-IMT change and other CVD risk factors (model 2). Panel V: Group C (individuals with previous CVD events), HR adjusted for
age, sex and annual mean CCA-IMT change (model 1). Panel VI: Group C (individuals with previous CVD events), HR adjusted for age, sex, annual mean CCA-IMT
change and other CVD risk factors (model 2).
https://doi.org/10.1371/journal.pone.0191172.g002
Fig 3. Meta-regression plot for the HR (combined endpoint) per SD of annual mean CCA-IMT change (model 1), by the correlation of baseline and follow-up
common CIMT. The size of each circle represents the precision of the log HR.
https://doi.org/10.1371/journal.pone.0191172.g003
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clear-cut. So perhaps an isolated investigation of CIMT is too limited. Unfortunately, given the
complex spatial structure of plaques, it is much more difficult to study plaque and plaque
change, compared to CIMT. The standardization process for plaque measurement is years
behind CIMT, where there is at least an international consensus.[54] Moreover, the amount of
data that is available to analyze plaque change with standardized measurements is considerably
lower than for CIMT change.
Linked with the previous argument, individuals with multiple risk factors, with carotid pla-
ques, and stroke or MI patients, are often subjected to intensive risk factor management, life
style modifications, and polypharmacy. Although we attempted to adjust for antihypertensive
and lipid lowering medication, complex interactions between risk factors, nutrition, exercise,
drugs and CIMT may obscure the association between CIMT and risk.
It is very important to distinguish between the ‘surrogacy’ at an individual level, as assessed
here, and surrogacy at a group level, which is important for the interpretation of clinical trials
about CIMT change. In this paper we addressed whether individuals whose CIMT progresses
have higher subsequent event risk. For the interpretation of clinical trials with the endpoint
CIMT change, we need to know whether a group of individuals treated with a drug whose
CIMT progressed on average less than another group treated with another drug (or placebo),
exhibits a lower event risk in the same period. This latter question has not been answered satis-
factorily yet, as the current findings are contradictory.[5,6] The criteria of surrogacy in clinical
trials, that is whether the effects of interventions on CIMT parallel the effects on risk, will be
addressed in stage 3 of the PROG-IMT project.[11]
Limitations
It may be argued that many of the individuals included here were already studied in our previ-
ous work on general population cohorts.[7] Three arguments counteract this point: First, we
selected only individuals at high cardiovascular risk out of these population cohorts. This
could well have improved the ratio between the hypothesized association, and measurement
error. Second, we added a number of population based studies [18, 20, 22, 24, 26, 39], risk
cohorts [21, 27, 31] and hospital cohorts [14, 30, 32, 34, 37, 41] since the above cited publica-
tion. These new cohorts (15 of 31) comprise 33% of the sample size, and 10% of the endpoint
events. Third, group C included only individuals that were explicitly excluded from the analy-
ses of our previous work.
Conclusions
Although common CIMT is associated with future CVD event risk, this is not apparently true
for common CIMT change over time. Reasons may include the complexity of atherosclerotic
process, and technical limits of current CIMT measurement.
Do these null findings mean that CIMT (change) is not scientifically useful? Our results
confirm that CIMT is still a very useful biomarker, with close associations with both risk fac-
tors and future endpoints. The change of CIMT, however, should be interpreted with care.
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